Log In
Print
BCIQ
Print
Print this Print this
 

R348

  Manage Alerts
Collapse Summary General Information
Company Rigel Pharmaceuticals Inc.
DescriptionTopical ophthalmic JAK kinase (JAK) and spleen tyrosine kinase (SYK) inhibitor
Molecular Target JAK kinase (JAK) ; Spleen tyrosine kinase (SYK)
Mechanism of ActionJanus kinase-3 (JAK-3) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today